Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

DRUG: Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)
DRUG: Placebo

PHASE4

Phase

COMPLETED

Status

Enrollment

OTHER

Sponsor class

Conditions

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia